Endo Pharmaceuticals Holdings Inc. (ENDP) sued to stop Mylan Inc. from marketing a generic copy of Frova before three patents on the migraine drug expire. Mylan, based in Canonsburg, Pennsylvania, is seeking approval to make and sell a version of the drug’s 2.5 milligram tablets, Endo said in a complaint filed today in federal court in Wilmington, Delaware. Endo, based in Chadds Ford, Pennsylvania, asked a judge to bar Mylan from infringing the patents. Frova, used to treat acute migraines in adults, was Endo’s fifth-biggest seller last year, according to data compiled by Bloomberg.
